This study day is ideal for nurses and those working in clinical trials centres and pharmaceutical companies. The day focuses on malignant melanoma, but much of the content is relevant to other solid tumours. Delegates do not need any prior knowledge of cell biology or genetics.
This course describes the recent advances made in targeted treatments for cancer, using malignant melanoma as the primary example. Delegates will learn about the faulty genes, pathways and proteins that drive malignant melanoma and other solid tumours, and the mechanism of action of targeted treatments such as B-Raf inhibitors and MEK inhibitors. The day also includes an overview of immunotherapy approaches for cancer, including T cell-based treatments and checkpoint inhibitors.